首页|Health Care Equity and Justice Scorecard To Increase Diversity in Clinical Trial Recruitment and Retention
Health Care Equity and Justice Scorecard To Increase Diversity in Clinical Trial Recruitment and Retention
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Amer Soc Nephrology
Black or African American and Hispanic or Latinx groups make up 13.4% and 18.4%, respectively, of the United States (US) population,1 yet they have the highest prevalence of CKD, up to 16% and 14%, respectively, compared with 13% for non-Latinx White people.2 Black or African American people also have a two- to four-fold greater incidence of kidney failure and a 3-fold greater risk of progressing to kidney failure, typically occurring at an earlier age and up to 5 years sooner than their White counterparts and accounting for 35% of adults with kidney failure. A key aspect to advancing health equity and ensuring access to high quality health care for all is by achieving increased diversity in clinical trials. The US Food and Drug Administration (FDA) 2020 Drug Trial Snapshot reports that only 11% Latinx and <10% Black or Asian, compared with 75% non-Latinx White participants were among the 32,000 participants enrolled in clinical trials. To ensure adequate diversity in clinical trial enrollment, trial sponsors should aim to mirror the demographic distribution of patients with the condition, and not simply reflect the US population. For example, clinical trials that target individuals with kidney failure should ensure that Black or African American individuals account for >35% of enrollment, and not 13%-14%, which approximates the US Black or African American population. Indeed, the FDA acknowledged the need to increase diversity in clinical trials so that individuals most likely to use the potential therapeutics are fully represented, and endorses strategies to overcome barriers to clinical trial enrollment for underrepresented populations.
Susanne B. Nicholas、Lilia Cervantes、on behalf of the Clinical Care、Innovation Workgroup of the American Society of Nephrology Health Care Justice Committee*
展开 >
Division of Nephrology, Department of Medicine, David Geffen School of Medicine at University of
NSTL
Amer Soc Nephrology
